General (Narrative) (Details) |
Mar. 16, 2021
shares
|
|---|---|
| Merger agreement with Chemomab, an Israeli limited company and a clinical-stage biotech company [Member] | |
| Restructuring Cost and Reserve [Line Items] | |
| Number of ADS issued and outstanding after the merger | 12.86 |